Radient Pharmaceuticals (NYSE: RPC) reported Q2 EPS of $0.24, $0.01 better than the analyst estimate of $0.23. Revenue for the quarter came in at $80.9 million versus the consensus estimate of $79.89 million.

For earnings history and earnings-related data on Radient Pharmaceuticals (RPC) click here.